checkAd

     439  0 Kommentare IMMUNOMEDICS ANNOUNCES ASCENT STUDY TO BE STOPPED FOR COMPELLING EFFICACY - Seite 3

    For More Information:

    Dr. Chau Cheng
    (862) 260-3727
    ccheng@immunomedics.com

    For Media Inquiries:

    Lesen Sie auch

    Darren Opland, Ph.D.
    (646) 627-8387
    Darren@lifescipublicrelations.com


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    IMMUNOMEDICS ANNOUNCES ASCENT STUDY TO BE STOPPED FOR COMPELLING EFFICACY - Seite 3 Decision based on recommendation from DSMC following study data review Sacituzumab govitecan has the potential to be the first FDA-approved antibody-drug conjugate for the treatment of metastatic triple-negative breast cancer Conference call and …